-
ESMO 2024 | Breakthrough in Immunotherapy: NICHE-2 Study Achieves 100% Three-Year Disease-Free Survival, Exceeding Expectations!
At the 2024 European Society for Medical Oncology (ESMO) Congress, Dr. Myriam Chalabi from Amsterdam, Netherlands, unveiled the latest results from the NICHE-2 study, showing a groundbreaking three-year disease-free survival (DFS) rate of 100% in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer undergoing neoadjuvant immunotherapy. This large-scale study provides critical evidence supporting neoadjuvant…
-
Shitong Huan: Improving Health Systems and Innovating Diagnostic and Treatment Tools to Eliminate Tuberculosis丨15th Tuberculosis Eastern Forum
Ending the “White Plague”: The Gates Foundation’s Ongoing Efforts and Achievements The Bill & Melinda Gates Foundation (Gates Foundation), founded in 2000, focuses on improving global health and development, particularly…
-
Dr. Feng Wang: Current Status and Challenges of Hepatocellular Carcinoma (HCC) Conversion Therapy in the Era of Integrated Medicine
Hepatology Digest: What is the core significance of conversion therapy for HCC under the concept of integrated medicine? How has it changed the traditional treatment approach for liver cancer? Dr.…
-
ESMO 2024 | Dr. Yao Zhu’s Team Explores Neoadjuvant Treatment Strategies for Localized High-Risk Prostate Cancer
The 2024 European Society for Medical Oncology (ESMO 2024) Annual Meeting took place from September 13 to 17 in Barcelona, Spain. The team led by Dr. Yao Zhu from Fudan University Shanghai Cancer Center presented their research on the neoadjuvant treatment of localized high-risk prostate cancer, featuring a combination of ARSi and PARPi, which was…
-
Peking Cancer Hospital Team’s PD-1/CTLA-4 Dual-Target Antibody Combined with Chemotherapy as First-Line Treatment for Advanced Gastric Cancer
Dr. Jiafu Ji, Dr. Ziyu Li, and Dr. Lin Shen from Peking Cancer Hospital have co-authored a research paper titled “Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial”, published online in Nature Medicine. The study addresses several critical clinical issues, such as the limited benefit of PD-1 monoclonal…
-
Dr. Rongping Guo: Durvalumab (PD-L1 Antibody) Combined with Lenvatinib and HAIC Offers a New Treatment Option for Advanced Liver Cancer Patients
The release of studies like HIMALAYA has marked the beginning of the dual immunotherapy era in advanced liver cancer treatment. As the majority of Chinese liver cancer patients are diagnosed at an advanced stage, finding the optimal systemic therapy, including durvalumab, in combination with local therapies to further improve patient outcomes has become a research…
-
ESMO China’s Voice丨Dr. Hongyan Tong’s Team: IMM01 Combined with Azacitidine as a New First-Line Treatment for CMML Shows 72.7% ORR in Phase II Study!
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held from September 13-17 in Barcelona, Spain. As one of the largest and most prestigious global clinical oncology conferences, it showcased groundbreaking research from experts around the world, advancing the field of oncology. In the hematologic malignancy space, this year’s ESMO also featured many…
-
ESMO China’s Voice丨Dr. Zhiming Li: Reshaping Hope, Exploring New Combination Therapy Strategies for R/R PTCL
From September 13 to 17, the 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. As one of the world’s leading oncology events, experts and scholars from across the globe gathered to share cutting-edge research results and explore future development directions. In the Mini Oral session on hematologic malignancies, Dr.…
Connecting Medical Expertise through Media